Previous 10 | Next 10 |
Esperion Therapeutics (ESPR) is trading ~3.9% lower in premarket after Goldman Sachs downgraded the stock to sell from neutral, citing the potential headwinds to the market launch of Nexletol/Nexlizet.The price target was lowered to $24 from $44 per share, implying a ~34.9% downside...
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Tuesday, February 23, 2021. Following the release, company management will h...
Esperion is deeply undervalued company selling a new treatment in the huge and lucrative market for lowering LDL cholesterol. ESPR is highly leveraged to Covid-reopening, but unlike many industries, it has gotten no bump from vaccine news. ESPR is financially healthy and will survive ...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with this event. For further details see: Esperion Therapeutics (ESPR) Presents At 39th Annual Healthcare Conference - Slideshow
On Wednesday morning, Biotech company Esperion Therapeutics (NASDAQ: ESPR) released unaudited preliminary results for the fourth quarter of its fiscal year 2020. However, investors don't seem too impressed with these results and they are selling off shares of the drugmaker as a resu...
Esperion (ESPR) announces it has entered into a definitive agreement with Serometrix to in-license its oral, small molecule PCSK9 inhibitor program, and says it expects Q4 2020 U.S. net product revenue to be between $8M and $8.5M.The small molecule PCSK9 inhibitor program is intended for...
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million – – Range represents over 140 percent sequential growth for NEXLETOL ® (bempedoic acid) tablets and NEXLIZET ® (bempedoic acid and ezetim...
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 7:30 a.m. Eastern Time. ...
Swiss authorities have approved Daiichi Sankyo Europe and Esperion Therapeutics' ([[ESPR]] -3.0%) Nilemdo (bempedoic acid) tablet and Nustendi (bempedoic acid and ezetimibe) tablet, for high low-density lipoprotein cholesterol.Bempedoic acid and its fixed combination drug product with ez...
- NILEMDO ® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and its fixed combination drug product with ezetimibe both deliver ...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...